About Ajanta Pharma Limited

Ajanta Pharma Limited is a specialty pharmaceuticals formulation company engaged in the development, manufacturing and marketing of specialty pharmaceutical finished dosages, with a well‑diversified Branded Generics business across India, Asia and Africa, alongside US Generics and an institutional anti‑malarial business in Africa. 

Incorporated on 31 December 1979, the company operates from Mumbai, India, and newly inaugurated its Corporate Headquarter in Andheri, Mumbai in FY 2025. 

Ajanta’s portfolio spans chronic and specialty therapies including cardiology, ophthalmology, dermatology and pain management, supported by a first‑to‑market strategy and front‑end presence in key markets  . The company’s footprint covers 30+ countries with 550+ products, 5,400+ medical representatives and 11,000+ employees; it has 52 active ANDAs with 47 products on shelf in the US, and runs seven state‑of‑the‑art manufacturing facilities in India (two US FDA‑approved; others WHO cGMP compliant). R&D is a core enabler, with 850+ scientists and total R&D spend of Rs 224 crore in FY 2025 (about 5% of revenue) .

Ajanta Pharma Limited’s Business Segments

• Branded Generics (India): India contributed 32% of total revenue in FY 2025; therapy mix of India sales was Cardiology 38%, Ophthalmology 29%, Dermatology 23% and Pain Management 10% (IQVIA MAT March 2025).
• Branded Generics (Asia & Africa): Asia contributed 26% and Africa 16% of total sales in FY 2025, driven by chronic therapies and new launches across nearly 30 markets in these regions.
• US Generics: Contributed 23% of revenue in FY 2025, with execution supported by 52 active ANDAs and 47 products on shelf.
• Africa Institutional (anti‑malarial): Contributed 3% of revenue in FY 2025, reflecting de‑growth on lower procurement by agencies; over 1 billion patients have been treated through this portfolio historically.
• Revenue by geography (FY 2025): India 32%, Asia 26%, Africa 16%, US 23%, Africa Institutional 3% (exports contributed 68% of revenue). .
• Revenue by industry vertical: Branded Generics accounted for 74% of revenue, US Generics 23% and Africa Institutional 3% in FY 2025.

Ajanta Pharma Limited Key Management

• Mannalal B. Agrawal, Chairman. Leads the Board of Directors and oversees governance of the company.
• Yogesh M. Agrawal, Managing Director. Responsible for overall management; co‑signed the FY 2025 letter to stakeholders.
• Rajesh M. Agrawal, Joint Managing Director. Supports executive management and co‑signed the FY 2025 letter to stakeholders.

Latest Updates on Ajanta Pharma Limited

• Strategic focus: Branded Generics reached a record 74% of revenue; India business added Gynaecology and Nephrology with 200 MRs and launched 32 new products (eight first‑to‑market).
• Capacity and launches: New state‑of‑the‑art liquid dosage block commissioned at Pithampur; five ANDA approvals and seven new ANDA filings; DCGI granted first‑time approval in India for a novel triple‑drug glaucoma/ocular‑hypertension combination  .
• Portfolio actions: First‑ever acquisition of three pain‑management brands in India; US Generics grew 9% for the year; Africa Institutional de‑grew 41% and now forms 3% of revenue  .
• Capital allocation: Distributed Rs 700 crore to shareholders in FY 2025 (H 350 crore dividend and Rs 350 crore buyback of 10,28,881 shares at Rs 2,770 per share).
• Recognitions and sustainability: Won ET Re‑Pharma Award for Excellence in Supply Chain; received Environmental Consciousness and Industry 4.0 awards from the Maharashtra Chief Minister; solar power met 34% of energy needs with total capacity at 12.6 MW, reducing CO2 emissions by 14,268 tonnes; company rated CARE AA+/A1+ during the year.